Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?

73 In a cohort of 1253 patients with DLBCL, PD-L1 protein expression was significantly associated with non-GCB subtype and Epstein-Barr virus (EBV) positivity and showed a trend toward inferior overall survival. 74 A meta-analysis demonstrated that 27% to 61% of DLBCL had PD-L1 expression, which was significantly associated with poor prognosis. 75 Checkpoint blockade in DLBCL has been of great interest; however, the response rate in unselected patients has only been 9% to 36% ( Table 3 ). 54 , 59 , 62 Given the association between 9p24.1 structural alteration and response to PD-1 inhibition seen in cHL and PMBCL, future studies should focus on DLBCL tumors with these alterations.

also in 53,322 other papers